Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
Authors
Trigo, J.Cho, B. C.
Park, K.
Girard, N.
Viteri, S.
Garrido, P.
Krebs, Matthew G
Thayu, M.
Knoblauch, R. E.
Xie, J.
Bauml, J. M.
Schnepp, R. W.
Londhe, A.
Mahadevia, P.
Leighl, N.
Issue Date
2022
Metadata
Show full item recordCitation
Trigo J, Cho BC, Park K, Girard N, Viteri S, Garrido P, et al. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S38–9.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.029Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.029Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.029